Compare · CGIX vs HUM
CGIX vs HUM
Side-by-side comparison of Cancer Genetics, Inc. (CGIX) and Humana Inc. (HUM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CGIX and HUM operate in Medical Specialities (Health Care), so they compete in similar markets.
- HUM carries a market cap of $53.25B.
- HUM has hit the wire 17 times in the past 4 weeks while CGIX has been quiet.
- HUM has more recent analyst coverage (25 ratings vs 0 for CGIX).
- Company
- Cancer Genetics, Inc.
- Humana Inc.
- Price
- -
- -
- Market cap
- -
- $53.25B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NYSE
- IPO
- n/a
- News (4w)
- 0
- 17
- Recent ratings
- 0
- 25
Humana Inc.
Humana Inc., together with its subsidiaries, operates as a health and well-being company in the United States. It operates through Retail, Group and Specialty, and Healthcare Services segments. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits. In addition, the company provides commercial fully-insured medical and specialty health insurance benefits comprising dental, vision, and other supplemental health benefits; and administrative services only products to individuals and employer groups, as well as military services, such as TRICARE T2017 East Region contract. Further, it offers pharmacy solutions, provider services, predictive modeling and informatics services, and clinical care services, such as home health and other services to its health plan members, as well as to third parties. As of December 31, 2020, the company had approximately 17 million members in medical benefit plans, as well as approximately 5 million members in specialty products. Humana Inc. was incorporated in 1964 and is headquartered in Louisville, Kentucky.
Latest CGIX
- SEC Form 4: John R Fletcher was granted 8,676 units of Common Stock
- SEC Form 4 filed by Marcus Boehm
- SEC Form 4 filed by Joanna Horobin
- SEC Form 4 filed by Howard Mcleod
- SEC Form 4 filed by Yung-Ping Yeh
- SEC Form 4 filed by R. Paul Hansen
- SEC Form 4 filed by E. Geoffrey Harris
- SEC Form 4 filed by Ralf Brandt
- SEC Form 4 filed by D.C. Andrew Lafrence
- SEC Form 4 filed by A John Roberts
Latest HUM
- Humana Foundation Marks 45 Years With Nearly $14 Million in Grants to Expand Healthy Food Access and Help Seniors Feel More Connected
- Humana to Launch National Gold Card Program to Reduce Prior Authorization Requirements
- Humana Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Humana Announces Final Results of Offers to Purchase for Cash Certain of its Outstanding Debt Securities
- Humana Announces Pricing Terms of Offers to Purchase for Cash Certain of its Outstanding Debt Securities
- Humana upgraded by RBC Capital Mkts with a new price target
- Director Frederick Wayne A.I. sold $193,853 worth of Humana Common (440 units at $440.57), closing all direct ownership in the company (SEC Form 4)
- President, Enterprise Growth Dintenfass David gifted 230 units of Humana Common, decreasing direct ownership by 0.91% to 25,177 units (SEC Form 4)
- Chief Legal Officer Ventura Joseph C sold $2,384,013 worth of Humana Common (5,495 units at $433.85) and gifted 437 units of Humana Common, decreasing direct ownership by 22% to 21,473 units (SEC Form 4)
- New oncology model from Humana, Evolent and American Oncology Network eliminates prior authorization burden